These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8991188)

  • 21. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
    J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
    J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
    Buzzoni R; Bonadonna G; Valagussa P; Zambetti M
    J Clin Oncol; 1991 Dec; 9(12):2134-40. PubMed ID: 1960555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
    Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P
    J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Formation of monoethylglycinexylidide (MEGX) in clinically healthy dogs.
    Neumann S; Frenz M; Streit F; Oellerich M
    Can J Vet Res; 2011 Oct; 75(4):317-20. PubMed ID: 22468031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent sequencing of full-dose CMF chemotherapy and radiation therapy in early breast cancer has no effect on treatment delivery.
    Faul C; Brufsky A; Gerszten K; Flickinger J; Kunschner A; Jacob H; Vogel V
    Eur J Cancer; 2003 Apr; 39(6):763-8. PubMed ID: 12651201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
    Smith IE; Powles TJ
    Oncology; 1993 Apr; 50 Suppl 1():9-15. PubMed ID: 8483562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of MEGX (monoethylglycinexylidide) and antipyrine tests in patients with liver cirrhosis.
    Wojcicki J; Kozlowski K; Drozdzik M; Wojcicki M
    Eur J Drug Metab Pharmacokinet; 2002; 27(4):243-7. PubMed ID: 12587953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis.
    Oellerich M; Burdelski M; Lautz HU; Schulz M; Schmidt FW; Herrmann H
    Ther Drug Monit; 1990 May; 12(3):219-26. PubMed ID: 2349604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
    Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
    J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (CMF regimen).
    Locatelli M; Colleoni M; Noberasco C; Nolé F; Orlando L; Munzone E; Peruzzotti G; Goldhirsch A
    Ann Oncol; 1999 Nov; 10(11):1394-5. PubMed ID: 10631475
    [No Abstract]   [Full Text] [Related]  

  • 34. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of the monoethylglycinexylidide test in pediatric liver transplant candidates.
    Burdelski M; Schütz E; Nolte-Buchholtz S; Armstrong VW; Oellerich M
    Ther Drug Monit; 1996 Aug; 18(4):378-82. PubMed ID: 8857554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG)
    J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of effectiveness of adjuvant alternating chemotherapy in node-positive, estrogen-receptor-negative premenopausal breast cancer patients: results of a multicentric Italian study. The Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group (GROCTA).
    Boccardo F; Rubagotti A; Amoroso D; Perrotta A; Sismondi P; Farris A; Mesiti M; Gallo L; Pacini P; Villa E; Agostara B
    Cancer Invest; 1997; 15(6):505-12. PubMed ID: 9412655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of metabolic liver function and hepatic blood flow during cardiopulmonary bypass.
    Autschbach R; Falk V; Lange H; Oellerich M; Walther T; Mohr FW; Dalichau H
    Thorac Cardiovasc Surg; 1996 Apr; 44(2):76-80. PubMed ID: 8782332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG).
    Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT
    Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
    Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y;
    Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.